

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.:	SERIAL NO.:	
		INFORMATION DISCLOSURE STATEMENT FOR PATENT		IN01630	10/667,856	
MAY 07 2004 O P T INFORMATION DISCLOSURE STATEMENT FOR PATENT Use several sheets if necessary)				APPLICANT:	Courtney and Laughlin	
				FILING DATE:	GROUP:	
				September 22, 2003	1617	
U. S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
KS	AA	Ezzet et al., "The pharmacokinetics of posaconazole in neutropenic oncology patients," <i>Abstract from the 41<sup>st</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy</i> ; Chicago, Illinois, USA; September 22-25, 2001, 41:4 (2001).				
KS	AB	Mellinghoff et al., "Use of posaconazole (SCH56592) for treatment of invasive fungal infections refractory to standard antifungal therapy" (Abstract from the 42 <sup>nd</sup> Annual Meeting of the American Society of Hematology; San Francisco, California, USA; December 01-05, 2000), <i>Blood</i> , 96(11 Part 2):341b (2000).				
KS	AC	Skiest et al., "Treatment of azole-refractory candidiasis in HIV disease," <i>Abstract from the 39<sup>th</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy</i> ; San Francisco, California, USA; September 26-29, 1999, 39:489 (1999).				
KS	AD	Petrailiene et al., "Correlation between serum galactomannan concentrations and antifungal efficacy of posaconazole (SCH 56592) in treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits," <i>Abstract from the 40<sup>th</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy</i> ; Toronto, Ontario, Canada; September 17-20, 2000, 40:380-381 (2000).				
KS	AE	Connolly et al., "Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice," <i>Antimicrobial Agents and Chemotherapy</i> , 44(10):2604-2608 (2000).				
EXAMINER <i>Kontamneni Sd/M</i>		DATE CONSIDERED <i>12/12/06</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						